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Background
To explore the impact of oxcarbazepine (OXC) mono-
therapy on terms of cognitive functions and academic
achievement in patients with benign childhood epilepsy
with centro-temporal spikes (BECTS).
Materials and methods
A total of 71 patients aged 5.6 to 11.4 years (45 males, 25
females, mean 8.5 ± 0.7) with typical clinical and EEG fea-
tures of BECTS were assigned to OXC monotherapy.
Inclusion criteria were a) newly diagnosed epilepsy, b) 3
or more seizures during the past 6 months c) normal
brain magnetic imaging. All of them underwent psycho-
metric assessment at screening and after 18 months of
treatment by means of WISC-III, Illinois Test of Psycho-
motor Abilities, DSM-IV, and Bender-Santucci Test. Sei-
zure types, frequency, awake and sleep EEG findings,
dosage ranges were documented. The Mann-Whitney U
test was used to describe differences 1) at initial evalua-
tion, comparing patients with a group of 45 age-matched
unaffected controls and 2) after 18 months of OXC mon-
otherapy, as an individual follow-up in the patient group.
Results
Cognitive assessment revealed learning deficits in 7/71
patients and 3/45 controls at baseline. This subgroup
marked difficulties in reasoning, computational skill,
phonological awareness and short-term visuospatial
memory. No child had a persistent stagnation or a regres-
sion in cognitive abilities after treatment. The identifica-
tion of these disabilities was crucial to the parents'
information and strategy development. The initial weak
scores in isolated domains improved or normalised dur-
ing the study with concomitant EEG improvement or nor-
malisation and effective seizure control.
Discussion
Oxcarbazepine is a novel antiepileptic drug with tested
efficacy and tolerability. Ours findings suggest that OXC
has a favourable cognitive profile and may prove a key
medication for improving the outcome of this epilepsy
syndrome
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